Literature DB >> 11018540

Binding of a de novo designed peptide to specific glycosaminoglycans.

G Jayaraman1, C W Wu, Y J Liu, K Y Chien, J C Fang, P C Lyu.   

Abstract

The binding of glycosaminoglycans to a synthetic peptide (SKAQKAQAKQAKQAQKAQKAQAKQAKQW-CONH(2)), consisting of a hybrid consensus heparin binding sequence, is studied using circular dichroism, fluorescence anisotropy and nuclear magnetic resonance techniques. The results unveil certain novel features, most importantly, the peptide binds preferentially to iduronic acid containing glycosaminoglycans and the dissociation constant for the peptide-heparin complex was found to be 30 nM. Interestingly, higher order intermolecular association(s)/aggregation was not observed, especially at saturating concentrations of the ligand. The helical structure of the peptide backbone, induced upon binding to a particular glycosaminoglycan is directly related to their binding affinity. In our opinion, studies on such unconventional hybrid peptide sequences containing low density basic amino acid residues would lead to the design of sequence specific glycosaminoglycan binding peptides.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018540     DOI: 10.1016/s0014-5793(00)01964-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Sallie Macy; Emily B Martin; Angela Williams; Keiichi Higuchi; Stephen J Kennel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

2.  Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.

Authors:  Daniel C Pimenta; Iseli L Nantes; Eduardo S de Souza; Bernard Le Bonniec; Amando S Ito; Ivarne L S Tersariol; Vitor Oliveira; Maria A Juliano; Luiz Juliano
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

3.  Specific Amyloid Binding of Polybasic Peptides In Vivo Is Retained by β-Sheet Conformers but Lost in the Disrupted Coil and All D-Amino Acid Variants.

Authors:  Jonathan S Wall; Angela Williams; Tina Richey; Alan Stuckey; Craig Wooliver; J Christopher Scott; Robert Donnell; Emily B Martin; Stephen J Kennel
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

4.  Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation.

Authors:  Emily B Martin; Stephen J Kennel; Tina Richey; Craig Wooliver; Dustin Osborne; Angela Williams; Alan Stuckey; Jonathan S Wall
Journal:  Peptides       Date:  2014-08-04       Impact factor: 3.750

5.  Novel heparan sulfate-binding peptides for blocking herpesvirus entry.

Authors:  Pranay Dogra; Emily B Martin; Angela Williams; Raphael L Richardson; James S Foster; Nicole Hackenback; Stephen J Kennel; Tim E Sparer; Jonathan S Wall
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

6.  Secondary structure propensity and chirality of the amyloidophilic peptide p5 and its analogues impacts ligand binding - In vitro characterization.

Authors:  Jonathan S Wall; Angela Williams; Craig Wooliver; Emily B Martin; Xiaolin Cheng; R Eric Heidel; Stephen J Kennel
Journal:  Biochem Biophys Rep       Date:  2016-08-11

Review 7.  The Diverse Functional Roles of Elongation Factor Tu (EF-Tu) in Microbial Pathogenesis.

Authors:  Kate L Harvey; Veronica M Jarocki; Ian G Charles; Steven P Djordjevic
Journal:  Front Microbiol       Date:  2019-10-24       Impact factor: 5.640

8.  A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo.

Authors:  Jonathan S Wall; Angela Williams; Tina Richey; Alan Stuckey; Ying Huang; Craig Wooliver; Sallie Macy; Eric Heidel; Neil Gupta; Angela Lee; Brianna Rader; Emily B Martin; Stephen J Kennel
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.